Showing 4691-4700 of 8849 results for "".
- New Skinder App May Help Med Students Spot Skin Cancerhttps://practicaldermatology.com/news/new-skinder-app-may-help-med-students-spot-skin-cancer/2457627/Skinder, a dermatologist-developed app, may help medical students learn to spot skin cancer. Skinder works like the matchmaking app Tinder. But instead of considering pictures of potential dates, swiping right if they’re attractive or left if they’re not, users consider high-r
- FDA Accepts Ortho Derm's Resubmission of NDA for Duobrii Lotion for Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-ortho-derms-resubmission-of-nda-for-duobrii-lotion-for-plaque-psoriasis/2457630/The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application (NDA) for Duobrii (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15,
- Lupin Launches Generic Clobetasol Cream in the UShttps://practicaldermatology.com/news/lupin-launches-generic-clobetasol-cream-in-the-us/2457637/Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier.
- Ortho Dermatologics Resubmits NDA for Duobrii Lotionhttps://practicaldermatology.com/news/ortho-dermatologics-resubmits-nda-for-duobrii-lotion/2457646/Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of p
- Revision Skincare Launches DEJ Eye Cream, DEJ Face Creamhttps://practicaldermatology.com/news/revision-launches-dej-eye-cream-dej-face-cream/2457648/Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- eRelevance Patient Engagement Survey Highlights Opportunities for Practiceshttps://practicaldermatology.com/news/erelevance-patient-engagement-survey-highlights-opportunities-for-practices/2457660/eRelevance Corporation, the leading provider of consumer engagement services for small- to medium-size businesses (SMBs) has released
- LEO Pharma to Acquire Bayer Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-to-acquire-bayer-prescription-dermatology-business/2457666/LEO Pharma has entered into a definitive agreement to buy Bayer's global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections, and rosacea and a range of topical steroids with an annual turnover in 2017 o
- Link Between Diet and Skin Disease Takes Center Stage at Summer AADhttps://practicaldermatology.com/news/link-between-diet-and-skin-disease-takes-center-stage-at-summer-aad/2457672/Dermatologists must help patients determine if there are any foods that may cause their skin condition to flare and provide evidence-based recommendations about next steps. “People looking to improve their skin health may think that changing their diet is the answer, but a derm
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti